Agile Therapeutics Past Earnings Performance
Past criteria checks 0/6
Agile Therapeutics's earnings have been declining at an average annual rate of -20.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 81.8% per year.
Key information
-20.8%
Earnings growth rate
14.5%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 81.8% |
Return on equity | n/a |
Net Margin | -157.8% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Agile Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 13 | -20 | 35 | 3 |
31 Dec 22 | 11 | -25 | 42 | 3 |
30 Sep 22 | 8 | -62 | 50 | 5 |
30 Jun 22 | 7 | -59 | 54 | 5 |
31 Mar 22 | 6 | -64 | 60 | 5 |
31 Dec 21 | 4 | -71 | 58 | 6 |
30 Sep 21 | 3 | -69 | 56 | 8 |
30 Jun 21 | 2 | -68 | 54 | 10 |
31 Mar 21 | 1 | -61 | 45 | 12 |
31 Dec 20 | 1 | -52 | 36 | 14 |
30 Sep 20 | 0 | -40 | 25 | 13 |
30 Jun 20 | 0 | -29 | 16 | 12 |
31 Mar 20 | 0 | -22 | 12 | 10 |
31 Dec 19 | 0 | -19 | 9 | 10 |
30 Sep 19 | 0 | -16 | 7 | 9 |
30 Jun 19 | 0 | -16 | 7 | 8 |
31 Mar 19 | 0 | -18 | 7 | 9 |
31 Dec 18 | 0 | -20 | 9 | 10 |
30 Sep 18 | 0 | -22 | 10 | 11 |
30 Jun 18 | 0 | -26 | 12 | 12 |
31 Mar 18 | 0 | -28 | 13 | 14 |
31 Dec 17 | 0 | -28 | 12 | 14 |
30 Sep 17 | 0 | -27 | 11 | 17 |
30 Jun 17 | 0 | -28 | 10 | 19 |
31 Mar 17 | 0 | -29 | 9 | 21 |
31 Dec 16 | 0 | -29 | 9 | 21 |
30 Sep 16 | 0 | -27 | 9 | 22 |
30 Jun 16 | 0 | -29 | 8 | 25 |
31 Mar 16 | 0 | -29 | 8 | 25 |
31 Dec 15 | 0 | -30 | 7 | 26 |
30 Sep 15 | 0 | -33 | 7 | 24 |
30 Jun 15 | 0 | -30 | 6 | 21 |
31 Mar 15 | 0 | -25 | 6 | 17 |
31 Dec 14 | 0 | -16 | 5 | 13 |
30 Sep 14 | 0 | -12 | 4 | 10 |
30 Jun 14 | 0 | -9 | 4 | 7 |
31 Mar 14 | 0 | -10 | 3 | 7 |
31 Dec 13 | 0 | -14 | 4 | 9 |
Quality Earnings: 0AL is currently unprofitable.
Growing Profit Margin: 0AL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0AL is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.
Accelerating Growth: Unable to compare 0AL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0AL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 0AL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.